The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 2017; 24:728–753.
2.
RossouwJE, AndersonGL, PrenticeRL, et al.Writing for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288:321–333.
3.
MansonJE, ChlebowskiRT, StefanickML, et al.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials. JAMA, 2013; 310:1353–1368.
4.
MansonJE, AragakiAK, RossouwJE, et al.Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The women's health initiative randomized trials. JAMA, 2017; 318:927–938.
5.
PinkertonJV, SantoroN. Compounded bioidentical hormone therapy: Identifying use trends and knowledge gaps among US women. Menopause, 2015; 22:926–936
6.
PinkertonJV, ConstantineGD. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: Results of a pharmacy survey. Menopause, 2016; 23:359–367.
7.
DubautJP, DongF, TjadenBL, et al.Prescribing bioidentical menopausal hormone therapy: A survey of physician views and practices. J Women's Health, 2018; 27:859–866.
8.
American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy. Obstet Gynecol, 2012; 120(2 Pt 1):411–415.
9.
SantenRJ, AllredDC, ArdoinSP, et al.Postmenopausal hormone therapy: An endocrine society scientific statement. J Clin Endocrinol Metab, 2010; 95:s1–s66.
10.
SantoroN, BraunsteinGD, ButtsCL, et al.Compounded bioidentical hormones in endocrinology practice: An endocrine society scientific statement. J Clin Endocrinol Metab, 2016; 101:1318.
11.
CobinRHPS, BledsoeMB, BorgWP, et al.American Association of Clinical Endocrinologists (AACE) Reproductive Medicine Committee Position Statement on Bioidentical Hormones updated July 15, 2007. Available at: www.aace.com/files/position-statements/aacebhstatement071507.pdf. Accessed May14, 2018.
12.
American Society for Reproductive Medicine Practice Committee. Committee Opinion No. 532: Compounded bioidentical menopausal hormone therapy. Fertil Steril, 2012; 98:308–312.
13.
Report 4 of the council on science and public health (I-16) Hormone Therapies: Off-Label Uses and Unapproved Formulations (Resolution 512-A-15) (Reference Committee K) CSAPH Report 4-I-16. Available at: www.ama-assn.org/sites/default/files/media…/2016-interim-csaph-report-4.pdf Accessed January19, 2018.
14.
McBaneSE, BorgeltLM, BarnesKN, et al.Use of compounded bioidentical hormone therapy in menopausal women: An opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy, 2014; 34:410–423.
15.
HawkinsJW, Roberto-NicholsDM, Stanley-HaneyJL. Guidelines for nurse practitioners in gynecologic settings, 10th edition. New York, NY: Springer Publishing Company, 2011:496.
16.
H.R.3204—Drug Quality and Security Act 113th Congress (2013–2014). Available at: www.congress.gov/bill/113th-congress/house-bill/3204 Accessed May14, 2018.
17.
Accreditation Commission for Health Care. Compounding pharmacy accreditation. Available at: www.achc.org/compounding-pharmacy.html Accessed May14, 2018.
18.
EdenJA, HackerNF, FortuneM. Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy. Med J Aust, 2007; 187:244–245.
19.
GassML, StuenkelCA, UtianWH, et al.Use of compounded hormone therapy in the United States: Report of The North American Menopause Society Survey. Menopause, 2015; 22:1276–1284.
